Natalizumab-PML survivors with subsequent MS treatment
Elisabeth Maillart
(1)
,
Jean-Sebastien Vidal
(2)
,
David Brassat
(3)
,
Bruno Stankoff
(4)
,
Agnès Fromont
(4)
,
Jérôme de Sèze
(5)
,
Frédéric Taithe
(6)
,
Pierre Clavelou
(6)
,
Bertrand Bourre
(7)
,
Valérie Delvaux
(8)
,
Audrey Rico
(9, 10, 11)
,
Pierre Labauge
(12)
,
Ayman Tourbah
(13)
,
Christine Lebrun
(14)
,
Jean Pelletier
(9, 10, 11)
,
Thibault Moreau
(4)
,
Céline Louapre
(1)
,
Catherine Lubetzki
(1)
,
Caroline Papeix
(1)
1
CHU Pitié-Salpêtrière [AP-HP]
2 Department of Gerontology, Broca Hospital, APHP, Paris
3 Département Neurologie [CHU Toulouse]
4 CHU Saint-Antoine [AP-HP]
5 Service de Neurologie générale, vasculaire et dégénérative (CHU de Dijon)
6 Department of Neurology, University Hospital of Clermont-Ferrand
7 Department of neurology, university hospital of Rouen
8 Department of Neurology, University Hospital of Liège, Belgium
9 Neurologie, maladies neuro-musculaires [Hôpital de la Timone - APHM]
10 CRMBM - Centre de résonance magnétique biologique et médicale
11 CEMEREM - Centre d'Exploration Métabolique par Résonance Magnétique [Hôpital de la Timone - APHM]
12 Department of Neurology, University Hospital of Montpellier
13 Department of Neurology (A.T.), University Hospital of Reims
14 Department of Neurology, University Hospital of Nice
2 Department of Gerontology, Broca Hospital, APHP, Paris
3 Département Neurologie [CHU Toulouse]
4 CHU Saint-Antoine [AP-HP]
5 Service de Neurologie générale, vasculaire et dégénérative (CHU de Dijon)
6 Department of Neurology, University Hospital of Clermont-Ferrand
7 Department of neurology, university hospital of Rouen
8 Department of Neurology, University Hospital of Liège, Belgium
9 Neurologie, maladies neuro-musculaires [Hôpital de la Timone - APHM]
10 CRMBM - Centre de résonance magnétique biologique et médicale
11 CEMEREM - Centre d'Exploration Métabolique par Résonance Magnétique [Hôpital de la Timone - APHM]
12 Department of Neurology, University Hospital of Montpellier
13 Department of Neurology (A.T.), University Hospital of Reims
14 Department of Neurology, University Hospital of Nice
Elisabeth Maillart
- Function : Author
- PersonId : 768189
- ORCID : 0000-0003-0108-4720
David Brassat
- Function : Author
- PersonId : 773701
- ORCID : 0000-0001-6430-305X
Bruno Stankoff
- Function : Author
- PersonId : 1146488
- ORCID : 0000-0002-9631-4674
- IdRef : 070067988
Pierre Labauge
- Function : Author
- PersonId : 759958
- ORCID : 0000-0001-7759-8555
- IdRef : 059860367
Jean Pelletier
- Function : Author
- PersonId : 756935
- ORCID : 0000-0001-9730-7567
- IdRef : 078804868
Céline Louapre
- Function : Author
- PersonId : 776330
- ORCID : 0000-0002-4987-1531
Caroline Papeix
- Function : Author
- PersonId : 764751
- ORCID : 0000-0003-4074-6125
- IdRef : 152876502
Abstract
Objective: To describe the clinico-radiologic outcome of MS patients with natalizumab-related progressive multifocal leukoencephalopathy (Nz-PML) surviving and receiving disease-modifying therapy (DMT). Methods: We describe clinical and radiologic evolution of Nz-PML survivors in an observational retrospective multicenter cohort to clarify the effect of different subsequent MS DMT strategies. Twenty-three patients from 11 centers were analyzed. Outcomes were (1) clinical efficacy of post-PML MS DMT, (2) radiologic efficacy of post-PML MS DMT, (3) radiologic evolution of PML lesion, and (4) disability progression. Results: There was no clinical worsening of PML symptoms with a stability of Expanded Disability Status Scale at the last follow-up. No relapse was reported with fingolimod and dimethyl fumarate. No radiologic worsening of Nz-PML lesion was observed at the end of the follow-up. Conclusion: In this large cohort of patients with Nz-PML, MS therapies given after Nz discontinuation were not associated with PML worsening. A larger cohort with longer follow-up will be necessary to confirm this therapeutic strategy.